XGN [NASD]
Exagen Inc.
Index- P/E- EPS (ttm)-2.35 Insider Own26.37% Shs Outstand17.08M Perf Week-18.09%
Market Cap30.48M Forward P/E- EPS next Y-2.40 Insider Trans0.00% Shs Float9.62M Perf Month3.75%
Income-40.10M PEG- EPS next Q-0.78 Inst Own76.60% Short Float / Ratio0.14% / 0.16 Perf Quarter-44.91%
Sales45.40M P/S0.67 EPS this Y-27.30% Inst Trans-1.20% Short Interest0.01M Perf Half Y-52.75%
Book/sh3.29 P/B0.76 EPS next Y11.10% ROA-35.30% Target Price7.50 Perf Year-75.32%
Cash/sh5.61 P/C0.44 EPS next 5Y- ROE-57.20% 52W Range2.10 - 11.69 Perf YTD-78.59%
Dividend- P/FCF- EPS past 5Y-2.90% ROI-21.50% 52W High-78.70% Beta-
Dividend %- Quick Ratio7.20 Sales past 5Y32.90% Gross Margin49.70% 52W Low18.57% ATR0.39
Employees219 Current Ratio7.20 Sales Q/Q19.50% Oper. Margin-83.30% RSI (14)45.02 Volatility9.12% 16.06%
OptionableYes Debt/Eq0.53 EPS Q/Q-11.90% Profit Margin-88.30% Rel Volume0.83 Prev Close2.62
ShortableYes LT Debt/Eq0.52 EarningsNov 14 AMC Payout- Avg Volume83.08K Price2.49
Recom1.70 SMA20-6.98% SMA50-6.50% SMA200-53.86% Volume68,614 Change-5.14%
Aug-05-22Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Oct-15-21Resumed Cowen Outperform $26
Apr-15-21Initiated Canaccord Genuity Buy $25
Nov-10-20Initiated KeyBanc Capital Markets Overweight $32
Oct-08-20Initiated BTIG Research Buy $18
Jun-02-20Resumed Cantor Fitzgerald Overweight $19 → $20
Oct-14-19Initiated William Blair Outperform
Oct-14-19Initiated Cowen Outperform $17
Oct-14-19Initiated Cantor Fitzgerald Overweight $18
Nov-14-22 07:55PM
04:05PM
Nov-08-22 04:05PM
Oct-31-22 04:05PM
Oct-17-22 09:00AM
08:25AM Loading…
Oct-04-22 08:25AM
Sep-20-22 04:05PM
Sep-19-22 10:20AM
Sep-01-22 04:05PM
Aug-05-22 12:00PM
Aug-04-22 06:55PM
04:06PM
04:05PM
Jul-25-22 04:05PM
Jul-21-22 04:05PM
08:25AM Loading…
Jul-05-22 08:25AM
Jun-21-22 08:10AM
Jun-09-22 08:25AM
May-26-22 04:05PM
May-16-22 04:05PM
May-11-22 05:55PM
04:06PM
04:05PM
May-10-22 10:45AM
May-03-22 05:15PM
May-01-22 12:00PM
Apr-25-22 04:05PM
Apr-20-22 04:05PM
Apr-12-22 07:22AM
Mar-30-22 08:25AM
10:00PM Loading…
Mar-22-22 10:00PM
05:25PM
04:06PM
04:05PM
Mar-16-22 04:05PM
Mar-09-22 05:35PM
04:05PM
Mar-08-22 04:05PM
Mar-07-22 08:05AM
Feb-24-22 05:40PM
Feb-08-22 02:38PM
Feb-02-22 04:05PM
Jan-12-22 10:46AM
Jan-09-22 12:00PM
Nov-17-21 04:05PM
Nov-11-21 08:30AM
Nov-10-21 05:55PM
04:05PM
Nov-04-21 04:05PM
Nov-03-21 03:01PM
Oct-27-21 04:05PM
08:25AM
Oct-25-21 08:25AM
Oct-21-21 04:05PM
Oct-13-21 11:05AM
Sep-13-21 04:15PM
Aug-10-21 07:01AM
Aug-09-21 06:35PM
04:05PM
Jul-30-21 08:25AM
Jul-29-21 08:25AM
Jul-26-21 04:06PM
Jul-20-21 03:02PM
Jul-15-21 07:04AM
Jul-13-21 04:05PM
Jun-22-21 09:25AM
Jun-18-21 08:29AM
May-24-21 04:05PM
May-12-21 02:30AM
May-11-21 04:05PM
02:30PM
May-04-21 04:05PM
03:00PM
May-03-21 08:25AM
Apr-27-21 04:05PM
Apr-16-21 09:45AM
Mar-29-21 08:25AM
Mar-25-21 04:15PM
Mar-22-21 10:01PM
04:05PM
Mar-16-21 11:30PM
05:25PM
04:05PM
02:30PM
Mar-12-21 08:33AM
Mar-09-21 12:30PM
Mar-03-21 06:06AM
Mar-02-21 08:00AM
Feb-22-21 04:05PM
Feb-15-21 08:58AM
Feb-03-21 04:05PM
Jan-22-21 07:22AM
Jan-21-21 04:05PM
Jan-10-21 06:00PM
Jan-05-21 04:05PM
Jan-04-21 04:05PM
08:30AM
Dec-11-20 08:35AM
Nov-18-20 04:05PM
Nov-16-20 08:25AM
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.